Adverum Biotechnologies Inc. - ADVM Net earnings per one share for the last twelve months

Public company logo of Adverum Biotechnologies (ADVM)

Adverum Biotechnologies (ADVM) develops innovative gene therapy methods for vision pathologies. This price chart on GURU.Markets reflects the EPS dynamics, which stand at -42.80. The elimination of the need for frequent injections guarantees the firm exceptional pricing power and high profitability. Simultaneously, the company adheres to ethical standards and minimizes environmental impact. Current drug development costs are fully offset by existing financial reserves.

ADVM Adverum Biotechnologies: Net earnings per share (EPS TTM) in the range 02/11/2024 - 12/20/2025

Financial and market metric breakdowns for adverum.com (ADVM)

- price and consensus price forecast:
Fundamental company valuation:ADVM, Adverum
Finished products of Adverum Biotechnologies

To minimize fundamental risks, it is essential to distinguish random accounting adjustments from real growth in earnings per share. In the case of Adverum Biotechnologies (ADVM), this allows for an assessment of how the commercialization of the IXIAR vector impacts the capitalization of the biopharmaceutical ecosystem. By analyzing EPS dynamics on a trailing twelve months (TTM) basis, an investor can track the average daily increase in net income, providing an objective market valuation of the business.

Competitor analysis

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|Net earnings per share for the last 12 months KALA|IRD - Net earnings per share for the trailing year|Earnings per share for the last twelve months okyopharma.com (OKYO)|OTLK - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters